Apremilast (Otezla®) is a first-in-class oral small molecule phosphodiesterase 4 (PDE4) inhibitor approved for the treatment of psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s Disease [18,19]. This evidence concerns the gene PDE4A and psoriatic arthritis.